|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM372522750 |
| 003 |
DE-627 |
| 005 |
20250306053128.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
240521s2024 xx |||||o 00| ||chi c |
| 024 |
7 |
|
|a 10.3760/cma.j.cn112140-20230928-00233
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n1241.xml
|
| 035 |
|
|
|a (DE-627)NLM372522750
|
| 035 |
|
|
|a (NLM)38763878
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a chi
|
| 100 |
1 |
|
|a Zhao, J C
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Clinical analysis of 18 children with aggressive mature B-cell lymphoma after liver transplantation
|
| 264 |
|
1 |
|c 2024
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 06.06.2024
|
| 500 |
|
|
|a Date Revised 06.06.2024
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Objective: To summarize the clinical characteristics, prognostic factors and treatment outcomes of childhood aggressive mature B-cell lymphoma after liver transplantation. Methods: This retrospective study included 18 children with newly diagnosed aggressive mature B-cell lymphoma after liver transplantation and treated from June 2018 to June 2022 in the Department of Hematology and Oncology of Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine. Clinical characteristics, treatment and outcomes of patients at last evaluation were analyzed. Overall survival (OS) and event free survival (EFS) rates were calculated by Kaplan-Meier method and Log-Rank analysis was performed to find factors of poor prognosis. Results: Among all 18 patients, there were 6 males and 12 females, and the age of onset was 40 (35, 54) months. The interval from transplant to tumor diagnosis was 21 (17, 35) months and 5 patients had early onset disease (<1 year since transplant). Seventeen patients had abdominal lesions. Diarrhea, vomiting and abdominal masses were the main clinical manifestations. All patients were Epstein-Barr virus (EBV) related posttransplant lymphoproliferative disorders (PTLD). One patient received individualized therapy due to critical sick at diagnosis, and the remaining 17 patients received CP (cyclophosphamide, methylprednisolone plus rituximab) and (or) modified EPOCH (prednisone, etoposide, doxorubicin, vincristine, cyclophosphamide plus rituximab) regimens. Of all 18 patients, 15 cases got complete response, 2 cases got partial response, 1 patient died of severe infection. The 2-year OS and EFS rates of 18 patients were (94±5)% and (83±8)%, respectively. None of age, gender or early onset disease had effect on OS and EFS rates in univariate analysis (all P>0.05). Conclusions: The symptoms of PTLD were atypical. Close surveillance of EBV-DNA for patients after liver transplantation was crucial to early stage PTLD diagnosis. CP or modified EPOCH regimen was efficient for pediatric patients with aggressive mature B cell lymphoma after liver transplantation
|
| 650 |
|
4 |
|a English Abstract
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
7 |
|a Cyclophosphamide
|2 NLM
|
| 650 |
|
7 |
|a 8N3DW7272P
|2 NLM
|
| 650 |
|
7 |
|a Vincristine
|2 NLM
|
| 650 |
|
7 |
|a 5J49Q6B70F
|2 NLM
|
| 650 |
|
7 |
|a Doxorubicin
|2 NLM
|
| 650 |
|
7 |
|a 80168379AG
|2 NLM
|
| 650 |
|
7 |
|a Prednisone
|2 NLM
|
| 650 |
|
7 |
|a VB0R961HZT
|2 NLM
|
| 700 |
1 |
|
|a Feng, M X
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Su, M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Han, Y L
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Xue, F
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Tang, Y J
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, A A
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Tang, J Y
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Gao, Y J
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Zhonghua er ke za zhi = Chinese journal of pediatrics
|d 1960
|g 62(2024), 6 vom: 02. Juni, Seite 553-558
|w (DE-627)NLM136249191
|x 0578-1310
|7 nnas
|
| 773 |
1 |
8 |
|g volume:62
|g year:2024
|g number:6
|g day:02
|g month:06
|g pages:553-558
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.3760/cma.j.cn112140-20230928-00233
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_20
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_31
|
| 912 |
|
|
|a GBV_ILN_39
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_50
|
| 912 |
|
|
|a GBV_ILN_61
|
| 912 |
|
|
|a GBV_ILN_65
|
| 912 |
|
|
|a GBV_ILN_69
|
| 912 |
|
|
|a GBV_ILN_70
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_120
|
| 912 |
|
|
|a GBV_ILN_130
|
| 912 |
|
|
|a GBV_ILN_227
|
| 912 |
|
|
|a GBV_ILN_244
|
| 912 |
|
|
|a GBV_ILN_285
|
| 912 |
|
|
|a GBV_ILN_294
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_665
|
| 912 |
|
|
|a GBV_ILN_813
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 62
|j 2024
|e 6
|b 02
|c 06
|h 553-558
|